Skip to main content
. 2021 Jun 25;8(1):119–130. doi: 10.14338/IJPT-20-00082.1

Table 1.

NPC and proton therapy study characteristics ordered by year published.

Study (year; country)
 Type
 N
 Modality
 Prescribed dose
 No. fraction
 Systemic therapy
 Stage
 Median FU, mo
 Outcomes at 2 y
% NACT
 % Con
 % Adj
 T1-2
 T3-4
 N0-1
 N2-3
 LRFS
 PFS
 OS
Holliday et al (2015; USA) [17] Retrospective, matched 10 20 IMPT IMRT 70 GyE 70 Gy 33–35 33–35 80 85 100 90 10 0 60 55 40 45 40 35 60 65 21.6 25.8 N = 10a N = 19a N = 9a N = 19a
Lewis et al (2016; USA) [18] Retrospective 10 IMPT 70 GyE 33–35 77.8 100 22.2 66.6 33.3 44.4 55.6 24.5 100 88.9 88.9
McDonald et al (2016; USA) [16]b Retrospective, matched 26 (15 NPC) 14 (2 NPC) IMRT 3D-PT 71.4 Gy 71.8 GyE 0 21.4 88.5 50 0 14.2 19.2 7.1 80.8 92.9 57.7 78.6 42.3 21.4
Beddok et al (2019; France) [19] Retrospective 17 Mixed-beam EBRTc/ DS-PT 70–78 GyE 35–39 65 100 0 100 100 0 98 94 88 88
Dionisi et al (2019; Italy) [20] Retrospective 17 rNPC 3D-PT 60 GyE (30.6–66) 1.8–2 Gy/Fx 11.8 47 0 5.9 88.2 0 0 10 72.9 59.3
Park et al (2019; Korea) [21] Retrospective 63 35 IMRT Mixed-beam IMRT/IMPT 68.4 GyE 68.4 GyE 30 30 0 0 100 100 0 0 Stage: II 12.7%, III 36.5%, IV 50.8% Stage: II 45.7%, III 22.9%, IV 31.4% 81 (1 y) 87.1 (1 y)
Sanford et al (2019; USA) [22] Retrospective 12 61 IMRT DS-PT 70 Gy 70 GyE 29 92 38 28 72 90 90 96 85 92
Alterio et al (2020; Italy) [23] Retrospective 17 27 IMRT Mixed-beam IMRT/IMPT 69.96–70 Gy 70–74 GyE 33–35 35–37 15 (88.2) 16 (59.3) 16 (94.1) 27 (100) 0 0 17 (100) 27 (100) 8 (47.1) 12 (44.4) 9 (52.9) 15 (55.6) 51 25 89 94 69 76 N = 15a N = 22a
Jiri et al (2020; Czech Republic) [24] Retrospective 40 IMPT 70–76 GyE 35–38 34 (85) 19 (44.5) 24 (56.5) 14 (32.5) 29 (67.5) 24 84 75 80

Abbreviations: NPC, nasopharyngeal cancer; GyE, Gray equivalent; FU, follow-up; NACT, neoadjuvant chemotherapy; Con, concurrent chemotherapy; Adj, adjuvant chemotherapy; LRFS, local and regional progression-free survival; PFS, progression-free survival; OS, overall survival; IMPT, intensity-modulated proton therapy; -, no information; IMRT, intensity-modulated radiation therapy; 3D-PT, 3-dimensional conformal proton therapy; EBRT, external beam radiation therapy; DS-PT, double-scattering proton therapy; rNPC, recurrent nasopharyngeal cancer; 3DCRT, 3-dimensional conformal radiation therapy.

a

At the time of last follow-up.

b

The study included nasopharyngeal and paranasal sinus sites. No separate outcome for each site was reported. The values shown in the table therefore represent the entire cohort.

c

EBRT = 3DCRT or IMRT.